echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JAMA Netw Open: Are prostate cancer drugs gonadotropin-releasing hormone agonists associated with cardiovascular disease risk and hypertension in men with diabetes?

    JAMA Netw Open: Are prostate cancer drugs gonadotropin-releasing hormone agonists associated with cardiovascular disease risk and hypertension in men with diabetes?

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer (PCa) is one of the most common cancers in men, with more than 1 million men diagnosed with prostate cancer worldwide in 2019. Men with PCa have a higher risk of cardiovascular disease (CVD) than men without PC.


    Studies have pointed to an increased risk of cardiovascular disease (CVD) in men with type 2 diabete.


    The study was a population-based cohort design and included longitudinal data from 2006 to 2016. Using these data, the researchers established 2 large cohorts consisting of men with and without PCa and men with and without GnRH agonist.


    The PCa cohort included 5714 men (median [IQR] age, 70 [10]) and the non-PCa cohort included 28,445 PCa-free men (median [IQR] age, 70 [10].


    Cumulative incidence of cardiovascular disease

    In conclusion, in this population-based cohort study, men with type 2 diabetes who received GnRH agonists for PCa had an increased risk of CV.


     

    Original source:

    E Lin, Hans Garmo, Mieke Van Hemelrijck et a.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.